Cargando…
Adverse cardiac events to monoclonal antibodies used for cancer therapy: The risk of Kounis syndrome
Monoclonal antibodies are currently used in the treatment of neoplastic, hematological, or inflammatory diseases, a practice that is occasionally associated with a variety of systemic and cutaneous adverse events. Cardiac adverse events include cardiomyopathy, ventricular dysfunction, arrhythmias, a...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Landes Bioscience
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4203633/ https://www.ncbi.nlm.nih.gov/pubmed/25340003 http://dx.doi.org/10.4161/onci.27987 |
_version_ | 1782340414188027904 |
---|---|
author | Kounis, Nicholas G Soufras, George D Tsigkas, Grigorios Hahalis, George |
author_facet | Kounis, Nicholas G Soufras, George D Tsigkas, Grigorios Hahalis, George |
author_sort | Kounis, Nicholas G |
collection | PubMed |
description | Monoclonal antibodies are currently used in the treatment of neoplastic, hematological, or inflammatory diseases, a practice that is occasionally associated with a variety of systemic and cutaneous adverse events. Cardiac adverse events include cardiomyopathy, ventricular dysfunction, arrhythmias, arrests, and acute coronary syndromes, such as acute myocardial infarction and vasospastic angina pectoris. These events generally follow hypersensitivity reactions including cutaneous erythema, pruritus chills, and precordial pain. Recently, IgE specific for therapeutic monoclonal antibodies have been detected, pointing to the existence of hypersensitivity and Kounis hypersensitivity-associated syndrome. Therefore, the careful monitoring of cardiovascular events is of paramount importance in the course of monoclonal antibody-based therapies. Moreover, further studies are needed to elucidate the pathophysiology of cardiovascular adverse events elicited by monoclonal antibodies and to identify preventive, protective, and therapeutic measures. |
format | Online Article Text |
id | pubmed-4203633 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Landes Bioscience |
record_format | MEDLINE/PubMed |
spelling | pubmed-42036332015-02-14 Adverse cardiac events to monoclonal antibodies used for cancer therapy: The risk of Kounis syndrome Kounis, Nicholas G Soufras, George D Tsigkas, Grigorios Hahalis, George Oncoimmunology Point of View Monoclonal antibodies are currently used in the treatment of neoplastic, hematological, or inflammatory diseases, a practice that is occasionally associated with a variety of systemic and cutaneous adverse events. Cardiac adverse events include cardiomyopathy, ventricular dysfunction, arrhythmias, arrests, and acute coronary syndromes, such as acute myocardial infarction and vasospastic angina pectoris. These events generally follow hypersensitivity reactions including cutaneous erythema, pruritus chills, and precordial pain. Recently, IgE specific for therapeutic monoclonal antibodies have been detected, pointing to the existence of hypersensitivity and Kounis hypersensitivity-associated syndrome. Therefore, the careful monitoring of cardiovascular events is of paramount importance in the course of monoclonal antibody-based therapies. Moreover, further studies are needed to elucidate the pathophysiology of cardiovascular adverse events elicited by monoclonal antibodies and to identify preventive, protective, and therapeutic measures. Landes Bioscience 2014-02-14 /pmc/articles/PMC4203633/ /pubmed/25340003 http://dx.doi.org/10.4161/onci.27987 Text en Copyright © 2014 Landes Bioscience http://creativecommons.org/licenses/by-nc/3.0/ This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited. |
spellingShingle | Point of View Kounis, Nicholas G Soufras, George D Tsigkas, Grigorios Hahalis, George Adverse cardiac events to monoclonal antibodies used for cancer therapy: The risk of Kounis syndrome |
title | Adverse cardiac events to monoclonal antibodies used for cancer therapy: The risk of Kounis syndrome |
title_full | Adverse cardiac events to monoclonal antibodies used for cancer therapy: The risk of Kounis syndrome |
title_fullStr | Adverse cardiac events to monoclonal antibodies used for cancer therapy: The risk of Kounis syndrome |
title_full_unstemmed | Adverse cardiac events to monoclonal antibodies used for cancer therapy: The risk of Kounis syndrome |
title_short | Adverse cardiac events to monoclonal antibodies used for cancer therapy: The risk of Kounis syndrome |
title_sort | adverse cardiac events to monoclonal antibodies used for cancer therapy: the risk of kounis syndrome |
topic | Point of View |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4203633/ https://www.ncbi.nlm.nih.gov/pubmed/25340003 http://dx.doi.org/10.4161/onci.27987 |
work_keys_str_mv | AT kounisnicholasg adversecardiaceventstomonoclonalantibodiesusedforcancertherapytheriskofkounissyndrome AT soufrasgeorged adversecardiaceventstomonoclonalantibodiesusedforcancertherapytheriskofkounissyndrome AT tsigkasgrigorios adversecardiaceventstomonoclonalantibodiesusedforcancertherapytheriskofkounissyndrome AT hahalisgeorge adversecardiaceventstomonoclonalantibodiesusedforcancertherapytheriskofkounissyndrome |